French Government Seeks Job Guarantees in Sanofi's Doliprane Sale

Amid potential sale to a US firm, France demands assurances on employment and domestic production for its top-selling medication.

Sanofi is in talks to sell a 50% stake in its Opella division, which includes Doliprane, to US private equity firm Clayton Dubilier & Rice.
The French government is pressuring for commitments to keep Doliprane production and jobs in France, reflecting concerns over national health sovereignty.
Economy Minister Antoine Armand and Industry Minister Marc Ferracci visited Sanofi's Lisieux site to discuss these concerns with employees and union representatives.
Unions and political figures across the spectrum have expressed fears about potential job losses and the impact on France's pharmaceutical independence.
The government is considering using foreign investment control procedures to ensure any sale includes strong guarantees for French interests.